ClinicalTrials.gov
public full text
Public Domain
Ph Ib/BGJ398/Cervix and Other Solid Tumors
This study will be conducted using 3+3 design and includes, a dose escalation part to define the MTDfRP2D for the combination of BGJ398 and carboplatin/paclitaxel, and a dose expansion part to treat another 12 patients (only cervix cancer) to further evaluate safety of this combination. Safety, tolerability and MTD will be determined in the dose escalation part of the study. The dose expansion will additionally investigate preliminary anti-tumor efficacy in cervical cancer. The dosing cycle is 21 days.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Serplulimab Plus Chemoradiotherapy for Stage III-IVA Cervical Cancer#834513
- VMAT Concurrent Cisplatin Plus Nab-paclitaxel for Local Advanced Cervical Cancer#907420
- A Trial for Patients With Advanced/Recurrent Cervical Cancer#830015
- A Phase III Study to Evaluate Efficacy and Safety of First-Line Treatment With HLX10 + Chemotherapy in Patients With Advanced Cervical Cancer#979749
- Radiation Therapy Plus Paclitaxel and Cisplatin in Treating Patients With Cervical Cancer#911364
Record · ID 917207
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive